|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:advocacy
|
required for participation
|
|
gptkbp:benefits
|
improved survival rates
|
|
gptkbp:clinical_trial
|
gptkb:United_States
Phase 1
Moderna, Inc.
to be published
overall survival
open-label study
Phase 1 and beyond
pending results
|
|
gptkbp:collaborations
|
academic partnerships
|
|
gptkbp:collaborator
|
gptkb:Merck_&_Co.
|
|
gptkbp:committee
|
independent committee
|
|
gptkbp:developed_by
|
Moderna, Inc.
|
|
gptkbp:dose_form
|
gptkb:liquid
|
|
gptkbp:eligibility
|
specific genetic markers
|
|
gptkbp:feedback
|
collected during trials
|
|
gptkbp:first_clinical_trial_date
|
gptkb:2021
|
|
gptkbp:funding
|
public and private funding
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Moderna's m RNA-4157
|
|
gptkbp:immune_response_type
|
adaptive immune response
|
|
gptkbp:impact
|
potential to change cancer treatment paradigm
|
|
gptkbp:indication
|
gptkb:Oncology
|
|
gptkbp:investigates
|
clinical researchers
|
|
gptkbp:investment
|
cancer therapeutics
|
|
gptkbp:is_effective_against
|
to be determined
|
|
gptkbp:is_monitored_by
|
during and after treatment
|
|
gptkbp:is_tested_for
|
tumor mutation burden
|
|
gptkbp:is_vulnerable_to
|
ongoing research
by healthcare professionals
messenger RNA
refrigerated conditions
|
|
gptkbp:mechanism_of_action
|
stimulates immune response
|
|
gptkbp:objective
|
evaluate safety and efficacy
|
|
gptkbp:part_of
|
cancer immunotherapy
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:platform
|
m RNA technology
|
|
gptkbp:project
|
early clinical development
|
|
gptkbp:publication
|
peer-reviewed journals
|
|
gptkbp:recruitment
|
ongoing
|
|
gptkbp:regulatory_approval_status
|
not approved yet
|
|
gptkbp:related_products
|
submitted to FDA
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:research_ethics_approval
|
obtained
|
|
gptkbp:research_focus
|
personalized cancer vaccines
|
|
gptkbp:research_institutes
|
various academic institutions
|
|
gptkbp:route_of_administration
|
injection
|
|
gptkbp:safety_features
|
under evaluation
|
|
gptkbp:scientific_goals
|
advancing cancer treatment
|
|
gptkbp:service_frequency
|
multiple doses
|
|
gptkbp:shipping_options
|
lipid nanoparticles
|
|
gptkbp:side_effect
|
to be assessed
|
|
gptkbp:status
|
in development
|
|
gptkbp:supply_chain
|
managed by Moderna
|
|
gptkbp:target_audience
|
patients with melanoma
|
|
gptkbp:targets
|
gptkb:Oncology
neoantigens
|
|
gptkbp:technology
|
therapeutic vaccine
|
|
gptkbp:type
|
gptkb:vaccine
|
|
gptkbp:year
|
gptkb:2023
|
|
gptkbp:bfsParent
|
gptkb:m_RNA_cancer_vaccine
|
|
gptkbp:bfsLayer
|
6
|